INCOMB

"Combating incontinence, from basic science to clinical practice"

 Coordinatore KAROLINSKA INSTITUTET 

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Prof.
Nome: Anders
Cognome: Arner
Email: send email
Telefono: +46 8 5248 2270
Fax: +46 8 343988

 Nazionalità Coordinatore Sweden [SE]
 Sito del progetto http://www.incomb.eu/
 Totale costo 4˙035˙977 €
 EC contributo 2˙908˙693 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-B
 Funding Scheme CP-FP
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-12-01   -   2012-05-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Prof.
Nome: Anders
Cognome: Arner
Email: send email
Telefono: +46 8 5248 2270
Fax: +46 8 343988

SE (STOCKHOLM) coordinator 0.00
2    Academisch Medisch Centrum bij de Universiteit van Amsterdam

 Organization address address: MEIBERGDREEF 9
city: AMSTERDAM
postcode: 1105AZ

contact info
Titolo: Mr.
Nome: Huub J.M
Cognome: Elstgeest
Email: send email
Telefono: +31 20 5666265
Fax: +31 20 6915462

NL (AMSTERDAM) participant 0.00
3    Hubert Andreas JOHN

 Organization address address: ENZERBNEHLSTRASSE 51
city: ZURICH
postcode: 8008

contact info
Titolo: Dr.
Nome: Hubert
Cognome: John
Email: send email
Telefono: +41 52 266 2982
Fax: +41 52 266 4503

CH (ZURICH) participant 0.00
4    LUNDS UNIVERSITET

 Organization address address: Paradisgatan 5c
city: LUND
postcode: 22100

contact info
Titolo: Dr.
Nome: Bengt
Cognome: Uvelius
Email: send email
Telefono: +46 46 171597
Fax: +46 46 211 2598

SE (LUND) participant 0.00
5    PFIZER LIMITED

 Organization address address: RAMSGATE ROAD
city: SANDWICH
postcode: CT13 9NJ

contact info
Titolo: Dr.
Nome: Chris
Cognome: Martin
Email: send email
Telefono: +44 1304 642359
Fax: +44 1304 652145

UK (SANDWICH) participant 0.00
6    QUEEN'S UNIVERSITY BELFAST

 Organization address address: University Road
city: BELFAST
postcode: BT7 1NN

contact info
Titolo: Dr.
Nome: Karen D
Cognome: Mccloskey
Email: send email
Telefono: +44 2890 972386

UK (BELFAST) participant 0.00
7    UNIVERSIDADE DO PORTO

 Organization address address: PRACA GOMES TEIXEIRA
city: PORTO
postcode: 4099 002

contact info
Titolo: Prof.
Nome: Francisco
Cognome: Cruz
Email: send email
Telefono: 351913000000
Fax: 351913000000

PT (PORTO) participant 0.00
8    UNIVERSITAET ZUERICH

 Organization address address: Raemistrasse 71
city: ZURICH
postcode: 8006

contact info
Titolo: Dr.
Nome: Caroline
Cognome: Maake
Email: send email
Telefono: +41 44 63 55338

CH (ZURICH) participant 0.00
9    UNIVERSITY COLLEGE LONDON

 Organization address address: GOWER STREET
city: LONDON
postcode: WC1E 6BT

contact info
Titolo: Prof.
Nome: Kent
Cognome: Lee
Email: send email
Telefono: +44 20 76796296
Fax: +44 20 7679 6502

UK (LONDON) participant 0.00
10    UNIVERSITY OF SURREY

 Organization address address: Stag Hill
city: GUILDFORD
postcode: GU2 7XH

contact info
Titolo: Ms.
Nome: Sue
Cognome: Angulatta
Email: send email
Telefono: +44 1483 682687
Fax: +44 1483 683791

UK (GUILDFORD) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

normal    urinary    communication    signaling    people    mechanisms    science    symptom    bladders    causes    treatments    receptors    urology    therapeutic    human    contractions    incontinence    wall    sensory    function    clinical    tissue    interstitial    therapy    distressing    urgency    active    overactive    oab    incomb    receptor    bladder    unknown    basic    conference    interaction    million    diagnostic    involving    trpv    cellular    cell    types    cells    translational    components    team    urodynamic    patients   

 Obiettivo del progetto (Objective)

'Incontinence affects almost 66 million people in the European Union. The Over Active Bladder (OAB) symptom complex is one of the major causes for incontinence, with a large number of affected persons and immense associated health care costs. The causes for the over active bladder contractions, underlying the urinary urgency of OAB are unknown, and current treatments are only partially effective. This collaborative and translational project, involving interaction between experimental and clinical urology scientists will focus on OAB and will characterize the different interacting cellular components and signaling systems in the wall of normal urinary bladders and OAB. The release of local mediators in the bladder wall, the properties of a newly described cell type (the interstitial cells, which may play a role in bladder over activity), the sensory signaling pathways (TRPV1-receptors), the receptor interaction and cellular communication are considered in order to create an integrated view on the mechanisms of bladder over activity. A strong emphasis is put on interaction between basic science and clinical applications, using a translational approach involving both specific animal models and human tissue from patients with defined urodynamic information. Several ethical and logistic issues with the use of human tissue are specifically addressed. An important further aspect of the experiments on human tissue is a direct analysis of the links between genetic and the urodynamic data of the patients, using unique biobanks. This will allow us further insight into the mechanisms of disease and possibly to identify new therapeutic targets. In close collaboration with a small company, we will develop an innovative potential physical therapy to affect bladder function. We will develop novel pharmacotherapeutic strategies and diagnostic tools, based on the characterization of cell properties, gene expression, receptors signaling systems of the bladder wall.'

Introduzione (Teaser)

A European project has just completed a comprehensive research programme into Overactive Bladder (OAB) syndrome. Aiming to relieve distressing symptoms for some 66 million Europeans, Incomb researchers have identified several new mechanisms of potential therapeutic value.

Descrizione progetto (Article)

The OAB symptom complex is one of the major causes of incontinence. OAB contractions result in 'urgency'. Not only are the reasons for this phenomenon largely unknown but current treatments are only partially effective or associated with adverse side effects.

The 'Combating incontinence, from basic science to clinical practice' (Incomb) project aimed to establish the pathogenesis of an overactive bladder and improvement of diagnostic tests. For maximum effectiveness, the consortium was made up of experts in lower urinary tract function but with a range of specialisations.

The Incomb team focused on communication between different cell types and developed new techniques to measure signalling components in the bladder lining, sensory nerves, smooth muscle and other cell types. In particular, interstitial cells were identified as particularly interesting as they modulate the contractile activity of the bladder wall. The structure and localisation of interstitial cells was compared in normal and diseased bladders.

Novel receptors were identified on the interstitial cells that could potentially be used for targeted therapy. Transient receptor potential vanilloid (TRPV) 1 receptors were found in different bladder cells and responded to stimulation by heat and acidity. These also offer possibilities for therapy as they are influenced by specific chemical compounds. Considering botulinum toxin as a potential therapy for OAB, the team examined the mechanisms and structural effects of the neurotoxin.

Dissemination has spanned all media outlets. The project has published 60 scientific papers, 39 reviews and 81 conference abstracts. Incomb also organised a major conference in Stockholm and a joint symposium between the EU project TRUST with support from the Swedish Enuresis Academy and the European Association for Urology.

New effective targeted therapies for OAB can significantly improve the quality of life for literally millions of people. Incomb results have also opened up several research corridors for further exploration of this distressing condition.

Altri progetti dello stesso programma (FP7-HEALTH)

GACD (2013)

Global Alliance for Chronic Diseases

Read More  

EVINCI-STUDY (2009)

Evaluation of Integrated Cardiac Imaging for the Detection and Characterization of Ischemic Heart Disease

Read More  

LIV-ES (2008)

Development of culture conditions for the differentiation of hES cells into hepatocytes

Read More